Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is conducting a Phase 3 ...

Itching is often the most debilitating cutaneous symptom of CKD and ESRD. Experts recommend a stepwise treatment approach ...

Following the FDA approval of linvoseltamab (Lynozyfic; Regeneron) for heavily pretreated multiple myeloma, Sundar Jagannath, MBBS, highlights its potential for earlier use, increased accessibility, ...

Mediolanum International Funds Ltd has supercharged its investment in Regeneron Pharmaceuticals, increasing its stake by a ...

Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical stage immuno-oncology company focused on the discovery and ...

The U.S. Court of Appeals for the First Circuit, in United States v. Regeneron, has joined the Sixth and Eighth Circuits in ...

Besides Wall Street's top-and-bottom-line estimates for Regeneron (REGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the ...

Q2 2025 net product revenue of $156.8 million, representing 52% year-over-year growth -- ARCALYST 2025 expected net product revenue increased to $625 - $640 million -- KPL-387 ...

Kiniksa expects its current operating plan to remain cash flow positive on an annual basis. Kiniksa will host a conference call and webcast at 8:30 a.m. Eastern Time on Tuesday, July 29, 2025, to ...

Over 100 prominent companies are currently engaged in developing treatments for osteoarthritis. Among them, Biosplice Therapeutics has drug candidates that have reached the most advanced stage—Phase ...

Paraspeak received critical acclaim at the Regeneron International Science and Engineering Fair (ISEF) 2025 in Ohio, where ...